AUTL
Autolus Therapeutics plc
Price Chart
Latest Quote
$1.55
+0.02 (+1.31%)
Current Price
| Previous Close | $1.53 |
| Open | $1.53 |
| Day High | $1.56 |
| Day Low | $1.50 |
| Volume | 1,782,697 |
Stock Information
| Shares Outstanding | 266.16M |
| Total Debt | $367.81M |
| Cash Equivalents | $201.63M |
| Revenue | $117.39M |
| Net Income | $-280.16M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $412.55M |
| EPS (TTM) | $-1.07 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $578.73M |
| Sales | $117.39M |
| Income | $-280.16M |
| Book/sh | $0.28 |
| Cash/sh | $0.76 |
| Employees | 752 |
Financial Ratios
| Quick Ratio | 4.06 |
| Current Ratio | 4.89 |
| Debt/Eq | 491.47 |
Returns & Margins
| ROA | -25.44% |
| ROE | -133.00% |
| Gross Margin | -74.60% |
| Operating Margin | -95.95% |
| Profit Margin | -238.65% |
Ownership
| Insider Ownership | 18.51% |
| Institutional Ownership | 63.43% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.43 |
| P/S | 3.51 |
| P/B | 5.52 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $8.72 |
Technical Indicators
| SMA20 | $1.70 |
| SMA50 | $1.96 |
| SMA200 | $1.66 |
| RSI | 31.94 |
| ATR | 0.0886 |
| Shares Float | 102.92M |
| Short Float | 4.87% |
| Short Ratio | 5.29 |
| Volatility | 2.14 |
| Rel Volume | 1.00 |
Performance History
| Week | -6.63% |
| Month | -16.67% |
| Quarter | +6.16% |
| 6 Months | +4.73% |
| YTD | -17.11% |
| Year | +1.31% |
| 3 Years | -39.45% |
| 5 Years | -74.04% |
| 10 Years | -93.80% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $1.55 | 1,784,300 |
| 2026-10-26 | $1.53 | 1,236,500 |
| 2026-10-23 | $1.54 | 1,530,900 |
| 2026-10-22 | $1.58 | 1,920,100 |
| 2026-10-21 | $1.62 | 1,825,500 |
| 2026-10-20 | $1.66 | 2,630,000 |
| 2026-10-19 | $1.59 | 1,522,200 |
| 2026-10-16 | $1.60 | 2,349,800 |
| 2026-10-15 | $1.72 | 1,486,300 |
| 2026-10-14 | $1.69 | 2,585,300 |
| 2026-10-13 | $1.62 | 2,414,200 |
| 2026-10-12 | $1.74 | 1,054,500 |
| 2026-10-09 | $1.81 | 1,476,000 |
| 2026-10-08 | $1.77 | 1,602,300 |
| 2026-10-07 | $1.81 | 1,550,200 |
| 2026-10-06 | $1.79 | 1,682,500 |
| 2026-10-05 | $1.83 | 2,521,400 |
| 2026-10-02 | $1.78 | 1,811,800 |
| 2026-10-01 | $1.85 | 1,458,900 |
| 2026-09-30 | $1.94 | 1,157,800 |
| 2026-09-29 | $1.86 | 1,769,200 |
| 2026-09-28 | $1.86 | 1,399,600 |
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
đ° Latest News
No news articles available at the moment. Check back later for updates on AUTL.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $96,369,000 | $11,387,000 | $0 | - |
| Cost Of Revenue | $96,369,000 | $11,387,000 | $0 | - |
| Total Revenue | $75,388,000 | $10,120,000 | $1,698,000 | $6,194,000 |
| Operating Revenue | $75,388,000 | $10,120,000 | $1,698,000 | $6,194,000 |
| Expenses | ||||
| Interest Expense | $36,670,000 | $9,294,000 | $45,067,000 | $8,905,000 |
| Total Expenses | $345,932,000 | $251,546,000 | $177,226,000 | $149,087,000 |
| Other Income Expense | $2,678,000 | $-769,000 | $-1,312,000 | $1,523,000 |
| Other Non Operating Income Expenses | $515,000 | $220,000 | $222,000 | $2,038,000 |
| Net Non Operating Interest Income Expense | $-17,690,000 | $23,061,000 | $-31,562,000 | $-7,197,000 |
| Interest Expense Non Operating | $36,670,000 | $9,294,000 | $45,067,000 | $8,905,000 |
| Operating Expense | $249,563,000 | $240,159,000 | $177,226,000 | $149,087,000 |
| General And Administrative Expense | - | - | $46,745,000 | $31,899,000 |
| Other Operating Expenses | - | - | - | $-166,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-287,528,000 | $-220,662,000 | $-208,383,000 | $-148,839,000 |
| Net Interest Income | $-17,690,000 | $23,061,000 | $-31,562,000 | $-7,197,000 |
| Interest Income | $18,980,000 | $32,355,000 | $13,505,000 | $1,708,000 |
| Normalized Income | $-289,236,770 | $-219,880,690 | $-206,849,140 | $-148,432,150 |
| Net Income From Continuing And Discontinued Operation | $-287,528,000 | $-220,662,000 | $-208,383,000 | $-148,839,000 |
| Total Operating Income As Reported | $-270,544,000 | $-241,426,000 | $-179,701,000 | - |
| Net Income Common Stockholders | $-287,528,000 | $-220,662,000 | $-208,383,000 | $-148,839,000 |
| Net Income | $-287,528,000 | $-220,662,000 | $-208,383,000 | $-148,839,000 |
| Net Income Including Noncontrolling Interests | $-287,528,000 | $-220,662,000 | $-208,383,000 | $-148,839,000 |
| Net Income Continuous Operations | $-287,528,000 | $-220,662,000 | $-208,383,000 | $-148,839,000 |
| Pretax Income | $-285,556,000 | $-219,134,000 | $-208,402,000 | $-148,567,000 |
| Interest Income Non Operating | $18,980,000 | $32,355,000 | $13,505,000 | $1,708,000 |
| Operating Income | $-270,544,000 | $-241,426,000 | $-175,528,000 | $-142,893,000 |
| Gross Profit | $-20,981,000 | $-1,267,000 | $1,698,000 | - |
| Special Income Charges | - | $-637,000 | $-4,173,000 | $-515,000 |
| Per Share | ||||
| Diluted EPS | $-1.08 | $-0.86 | $-1.20 | $-1.57 |
| Basic EPS | $-1.08 | $-0.86 | $-1.20 | $-1.57 |
| Other | ||||
| Tax Effect Of Unusual Items | $454,230 | $-207,690 | $-140 | $-108,150 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-241,235,000 | $-201,135,000 | $-155,236,000 | $-131,725,000 |
| Total Unusual Items | $2,163,000 | $-989,000 | $-1,534,000 | $-515,000 |
| Total Unusual Items Excluding Goodwill | $2,163,000 | $-989,000 | $-1,534,000 | $-515,000 |
| Reconciled Depreciation | $9,814,000 | $7,716,000 | $6,565,000 | $7,422,000 |
| EBITDA (Bullshit earnings) | $-239,072,000 | $-202,124,000 | $-156,770,000 | $-132,240,000 |
| EBIT | $-248,886,000 | $-209,840,000 | $-163,335,000 | $-139,662,000 |
| Diluted Average Shares | $266,138,224 | $255,161,038 | $173,941,926 | $94,993,400 |
| Basic Average Shares | $266,138,224 | $255,161,038 | $173,941,926 | $94,993,400 |
| Diluted NI Availto Com Stockholders | $-287,528,000 | $-220,662,000 | $-208,383,000 | $-148,839,000 |
| Tax Provision | $1,972,000 | $1,528,000 | $-19,000 | $272,000 |
| Gain On Sale Of Security | $2,163,000 | $-989,000 | $2,639,000 | - |
| Research And Development | $117,689,000 | $138,436,000 | $130,481,000 | $117,354,000 |
| Selling General And Administration | $131,874,000 | $101,723,000 | $46,745,000 | $31,899,000 |
| Gain On Sale Of Ppe | - | $-223,000 | $-3,791,000 | $-515,000 |
| Impairment Of Capital Assets | - | $414,000 | $382,000 | $0 |
| Other Gand A | - | - | $46,745,000 | $31,899,000 |
Fetched: 2026-10-02
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $158,320,000 | $414,952,000 | $111,474,000 | $298,674,000 |
| Total Assets | $589,068,000 | $782,725,000 | $375,381,000 | $490,274,000 |
| Total Non Current Assets | $153,153,000 | $121,796,000 | $100,079,000 | $64,503,000 |
| Other Non Current Assets | $249,000 | $170,000 | $380,000 | $2,176,000 |
| Non Current Prepaid Assets | $1,032,000 | $963,000 | $983,000 | $1,832,000 |
| Non Current Deferred Assets | $3,560,000 | $3,239,000 | $3,063,000 | $2,076,000 |
| Non Current Deferred Taxes Assets | $3,560,000 | $3,239,000 | $3,063,000 | $2,076,000 |
| Goodwill And Other Intangible Assets | $19,809,000 | $12,373,000 | $0 | $0 |
| Other Intangible Assets | $19,809,000 | $12,373,000 | - | - |
| Current Assets | $435,915,000 | $660,929,000 | $275,302,000 | $425,771,000 |
| Current Deferred Assets | $3,429,000 | $2,320,000 | $1,787,000 | $1,494,000 |
| Restricted Cash | $1,503,000 | $1,425,000 | $769,000 | $325,000 |
| Prepaid Assets | $21,275,000 | $15,212,000 | $8,638,000 | $12,337,000 |
| Inventory | $33,209,000 | $4,138,000 | $0 | - |
| Receivables | $75,789,000 | $48,240,000 | $24,542,000 | $28,976,000 |
| Other Receivables | $47,314,000 | $39,663,000 | $20,663,000 | $26,154,000 |
| Taxes Receivable | $3,577,000 | $5,996,000 | $2,771,000 | $2,701,000 |
| Accrued Interest Receivable | $874,000 | $2,566,000 | $999,000 | - |
| Accounts Receivable | $24,024,000 | $15,000 | $109,000 | $121,000 |
| Cash Cash Equivalents And Short Term Investments | $300,710,000 | $588,023,000 | $239,566,000 | $382,436,000 |
| Cash And Cash Equivalents | $104,132,000 | $227,380,000 | $239,566,000 | $382,436,000 |
| Other Current Assets | - | $1,571,000 | - | $203,000 |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Total Debt | $71,387,000 | $52,629,000 | $52,967,000 | $24,256,000 |
| Long Term Debt And Capital Lease Obligation | $66,822,000 | $49,631,000 | $47,914,000 | $19,218,000 |
| Current Debt And Capital Lease Obligation | $4,565,000 | $2,998,000 | $5,053,000 | $5,038,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $410,939,000 | $355,400,000 | $263,907,000 | $191,600,000 |
| Total Non Current Liabilities Net Minority Interest | $337,499,000 | $294,657,000 | $219,170,000 | $145,234,000 |
| Other Non Current Liabilities | $270,200,000 | $244,600,000 | $170,899,000 | $125,900,000 |
| Tradeand Other Payables Non Current | $477,000 | $426,000 | $357,000 | $116,000 |
| Current Liabilities | $73,440,000 | $60,743,000 | $44,737,000 | $46,366,000 |
| Other Current Liabilities | $17,019,000 | $3,979,000 | $533,000 | $393,000 |
| Payables And Accrued Expenses | $25,632,000 | $34,085,000 | $24,394,000 | $30,754,000 |
| Payables | $3,083,000 | $5,563,000 | $103,000 | $531,000 |
| Total Tax Payable | $0 | $3,594,000 | $0 | - |
| Accounts Payable | $3,083,000 | $1,969,000 | $103,000 | $531,000 |
| Equity | ||||
| Common Stock Equity | $178,129,000 | $427,325,000 | $111,474,000 | $298,674,000 |
| Total Equity Gross Minority Interest | $178,129,000 | $427,325,000 | $111,474,000 | $298,674,000 |
| Stockholders Equity | $178,129,000 | $427,325,000 | $111,474,000 | $298,674,000 |
| Other Equity Interest | $118,000 | $118,000 | $118,000 | $118,000 |
| Gains Losses Not Affecting Retained Earnings | $-5,356,000 | $-29,174,000 | $-28,992,000 | $-38,898,000 |
| Other Equity Adjustments | $-5,356,000 | $-29,174,000 | $-28,992,000 | $-38,898,000 |
| Retained Earnings | $-1,386,752,000 | $-1,099,224,000 | $-878,562,000 | $-670,179,000 |
| Other | ||||
| Ordinary Shares Number | $266,143,286 | $266,121,689 | $174,101,361 | $173,074,510 |
| Share Issued | $266,143,286 | $266,121,689 | $174,101,361 | $173,074,510 |
| Tangible Book Value | $158,320,000 | $414,952,000 | $111,474,000 | $298,674,000 |
| Invested Capital | $178,129,000 | $427,325,000 | $111,474,000 | $298,674,000 |
| Working Capital | $362,475,000 | $600,186,000 | $230,565,000 | $379,405,000 |
| Capital Lease Obligations | $71,387,000 | $52,629,000 | $52,967,000 | $24,256,000 |
| Total Capitalization | $178,129,000 | $427,325,000 | $111,474,000 | $298,674,000 |
| Additional Paid In Capital | $1,570,107,000 | $1,555,593,000 | $1,018,902,000 | $1,007,625,000 |
| Capital Stock | $12,000 | $12,000 | $8,000 | $8,000 |
| Common Stock | $12,000 | $12,000 | $8,000 | $8,000 |
| Long Term Capital Lease Obligation | $66,822,000 | $49,631,000 | $47,914,000 | $19,218,000 |
| Current Capital Lease Obligation | $4,565,000 | $2,998,000 | $5,053,000 | $5,038,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $26,224,000 | $19,681,000 | $14,757,000 | $10,181,000 |
| Current Accrued Expenses | $22,549,000 | $28,522,000 | $24,291,000 | $30,223,000 |
| Net PPE | $128,503,000 | $105,051,000 | $95,653,000 | $58,419,000 |
| Accumulated Depreciation | $-44,394,000 | $-34,618,000 | $-28,774,000 | $-25,647,000 |
| Gross PPE | $172,897,000 | $139,669,000 | $124,427,000 | $84,066,000 |
| Leases | $15,762,000 | $14,116,000 | $12,728,000 | $11,688,000 |
| Construction In Progress | $27,075,000 | $19,638,000 | $12,539,000 | $13,186,000 |
| Other Properties | $120,526,000 | $97,226,000 | $93,023,000 | $54,398,000 |
| Machinery Furniture Equipment | $9,534,000 | $8,689,000 | $6,137,000 | $4,794,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $5,395,000 | $140,000 | $0 | - |
| Work In Process | $3,633,000 | $16,000 | $0 | - |
| Raw Materials | $24,181,000 | $3,982,000 | $0 | - |
| Other Short Term Investments | $196,578,000 | $360,643,000 | $0 | - |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-10-02
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-310,700,000 | $-241,090,000 | $-156,573,000 | $-123,149,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-283,568,000 | $-206,271,000 | $-145,587,000 | $-112,308,000 |
| Cash Flow From Continuing Operating Activities | $-283,568,000 | $-206,271,000 | $-145,587,000 | $-112,308,000 |
| Operating Gains Losses | $-3,153,000 | $2,121,000 | $-3,813,000 | $4,511,000 |
| Investing Activities | ||||
| Capital Expenditure | $-27,132,000 | $-34,819,000 | $-10,986,000 | $-10,841,000 |
| Investing Cash Flow | $158,458,000 | $-394,552,000 | $-10,986,000 | $-10,841,000 |
| Cash Flow From Continuing Investing Activities | $158,458,000 | $-394,552,000 | $-10,986,000 | $-10,841,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $549,977,000 | $0 | $163,854,000 |
| Financing Cash Flow | $-4,339,000 | $589,554,000 | $-883,000 | $223,610,000 |
| Cash Flow From Continuing Financing Activities | $-4,339,000 | $589,554,000 | $-883,000 | $223,610,000 |
| Net Other Financing Charges | $-4,339,000 | $38,975,000 | $-910,000 | $59,639,000 |
| Net Common Stock Issuance | $0 | $549,977,000 | $0 | $163,854,000 |
| Common Stock Issuance | $0 | $549,977,000 | $0 | $163,854,000 |
| Other | ||||
| Income Tax Paid Supplemental Data | $1,968,000 | $2,391,000 | $551,000 | $471,000 |
| End Cash Position | $105,635,000 | $228,805,000 | $240,335,000 | $382,761,000 |
| Beginning Cash Position | $228,805,000 | $240,335,000 | $382,761,000 | $310,676,000 |
| Effect Of Exchange Rate Changes | $6,279,000 | $-261,000 | $15,030,000 | $-28,376,000 |
| Changes In Cash | $-129,449,000 | $-11,269,000 | $-157,456,000 | $100,461,000 |
| Proceeds From Stock Option Exercised | $0 | $602,000 | $27,000 | $117,000 |
| Net Investment Purchase And Sale | $185,590,000 | $-359,733,000 | $0 | - |
| Sale Of Investment | $428,209,000 | $0 | - | - |
| Purchase Of Investment | $-242,619,000 | $-359,733,000 | $0 | - |
| Net Intangibles Purchase And Sale | $-8,089,000 | $-12,744,000 | $0 | - |
| Purchase Of Intangibles | $-8,089,000 | $-12,744,000 | $0 | - |
| Net PPE Purchase And Sale | $-19,043,000 | $-22,075,000 | $-10,986,000 | $-10,841,000 |
| Purchase Of PPE | $-19,043,000 | $-22,075,000 | $-10,986,000 | $-10,841,000 |
| Change In Working Capital | $-51,989,000 | $-23,655,000 | $292,000 | $536,000 |
| Change In Other Current Liabilities | $14,645,000 | $-369,000 | $-13,555,000 | $-4,687,000 |
| Change In Payables And Accrued Expense | $2,340,000 | $13,524,000 | $489,000 | $16,029,000 |
| Change In Accrued Expense | $1,040,000 | $11,934,000 | $998,000 | $16,007,000 |
| Change In Payable | $1,300,000 | $1,590,000 | $-509,000 | $22,000 |
| Change In Account Payable | $1,300,000 | $1,590,000 | $-509,000 | $22,000 |
| Change In Prepaid Assets | $-4,566,000 | $-32,581,000 | $13,358,000 | $-10,806,000 |
| Change In Inventory | $-40,250,000 | $-4,229,000 | $0 | - |
| Change In Receivables | $-24,158,000 | $0 | - | - |
| Changes In Account Receivables | $-24,158,000 | $0 | - | - |
| Other Non Cash Items | $22,508,000 | $12,508,000 | $49,152,000 | $12,316,000 |
| Stock Based Compensation | $14,438,000 | $15,472,000 | $11,204,000 | $12,014,000 |
| Asset Impairment Charge | $12,628,000 | $414,000 | $382,000 | $0 |
| Deferred Tax | $-286,000 | $-185,000 | $-986,000 | $-268,000 |
| Deferred Income Tax | $-286,000 | $-185,000 | $-986,000 | $-268,000 |
| Depreciation Amortization Depletion | $9,814,000 | $7,716,000 | $6,565,000 | $7,422,000 |
| Depreciation And Amortization | $9,814,000 | $7,716,000 | $6,565,000 | $7,422,000 |
| Amortization Cash Flow | $1,518,000 | $162,000 | $0 | - |
| Amortization Of Intangibles | $1,518,000 | $162,000 | $0 | - |
| Depreciation | $8,296,000 | $7,554,000 | $6,565,000 | - |
| Net Foreign Currency Exchange Gain Loss | $-3,167,000 | $1,898,000 | $-7,604,000 | $3,996,000 |
| Gain Loss On Sale Of PPE | $14,000 | $223,000 | $3,791,000 | $515,000 |
| Net Income From Continuing Operations | $-287,528,000 | $-220,662,000 | $-208,383,000 | $-148,839,000 |
| Change In Other Current Assets | - | - | - | - |
Fetched: 2026-10-02